Methods of cancer treatment using Anti-ox40 antibodies in combination with Anti-PD1 antibodies
Patent Information
- Application Number
- PCT/CN2024/095170
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-06-02
- Filing Date
- 2024-05-24
- Publication Date
- 2024-11-28
Smart Images

Figure CN2024095170_28112024_PF_FP_ABST
Abstract
Description
METHODS OF CANCER TREATMENT USING ANTI-OX40 ANTIBODIES IN COMBINATION WITH ANTI-PD1 ANTIBODIES
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of priority of US Provisional Patent Application No. 63 / 504,373, filed May 25, 2023, entitled “METHODS OF CANCER TREATMENT USING ANTI-OX40 ANTIBODIES IN COMBINATION WITH ANTI-PD1 ANTIBODIES, ” and US Provisional Patent Application No. 63 / 505,761, filed June 2, 2023, entitled “METHODS OF CANCER TREATMENT USING ANTI-OX40 ANTIBODIES IN COMBINATION WITH ANTI-PD1 ANTIBODIES, ” which are hereby incorporated by reference in their entireties.
[0003] FIELD OF THE DISCLOSURE
[0004] Disclosed herein is a method treating cancer using a combination of antibodies or antigen-binding fragments thereof that bind to human OX40 and human PD1.BACKGROUND
[0005] OX40 (also known as ACT35, CD134, or TNFRSF4) is an approximately 50 kDa type I transmembrane glycoprotein, and a member of the tumor necrosis factor receptor super family (TNFRSF) (Croft, 2010; Gough and Weinberg, 2009) . Mature human OX40 is composed of 249 amino acid (AA) residues, with a 37 AA cytoplasmic tail and a 185 AA extracellular region. The extracellular domain of OX40 contains three complete and one incomplete cysteine-rich domains (CRDs) . The intracellular domain of OX40 contains one conserved signaling-related QEE motif, which mediates binding to several TNFR-associated factors (TRAF) including TRAF2, TRAF3, and TRAF5, allowing OX40 to link to intracellular kinases (Arch and Thompson, 1998; Willoughby et al., 2017) .
[0006] OX40 was initially discovered on activated rat CD4+ T cells, and murine and human homologs were subsequently cloned from T cells (al-Shamkhani et al., 1996; Calderhead et al., 1993) . In addition to expression on activated CD4+ T cells, including T helper (Th) 1 cells, Th2 cells, Th17 cells, as well as regulatory T (Treg) cells, OX40 expression has also been found on the surface of activated CD8+ T cells, natural killer (NK) T cells, neutrophils, and NK cells (Croft, 2010) . In contrast, low OX40 expression is found on CD4+ and CD8+ T cells, as well as on most resting memory T cells (Croft, 2010; Soroosh et al., 2007) . The surface expression of OX40 on T cells is transient. After TCR activation, OX40 expression on T cells is greatly increased within 24 hours and with peaks in 2~3 days, persisting for 5~6 days (Gramaglia et al., 1998) .
[0007] In normal tissues, OX40 expression is low and is mainly on lymphocytes in lymphoid organs (Durkop et al., 1995) . However, upregulation of OX40 expression on immune cells have frequently been observed in both animal models and human patients with pathological conditions (Redmond and Weinberg, 2007) , such as autoimmune diseases (Carboni et al., 2003; Jacquemin et al., 2015; Szypowska et al., 2014) and cancers (Kjaergaard et al., 2000; Vetto et al., 1997; Weinberg et al., 2000) . Notably, the increased expression of OX40 is associated with longer survival in patients with colorectal cancer and cutaneous melanoma, and inversely correlates with the occurrence of distant metastases and more advanced tumor features (Ladanyi et al., 2004; Petty et al., 2002; Sarff et al., 2008) . It has also been shown that anti-OX40 antibody treatment could elicit anti-tumor efficacy in various mouse models (Aspeslagh et al., 2016) , indicating the potential of OX40 as an immunotherapeutic target. In the first clinical trial in cancer patients, conducted by Curti et al., evidence of anti-tumor efficacy and activation of tumor-specific T cells was observed with an agonistic anti-OX40 monoclonal antibody, indicating that OX40 antibodies have utility in boosting anti-tumor T-cell responses (Curti et al., 2013) .
[0008] The mechanisms of action of agonistic anti-OX40 antibodies in mediating anti-tumor efficacy have been studied primarily in mouse tumor models (Weinberg et al., 2000) . Until recently, the mechanism of action of agonistic anti-OX40 antibodies in tumors was attributed to their ability to trigger a co-stimulatory signaling pathway in effector T cells, as well as the inhibitory effects on the differentiation and functions of Treg cells (Aspeslagh et al., 2016; Ito et al., 2006; St Rose et al., 2013; Voo et al., 2013) . Recent studies have shown that in both animal tumor models and cancer patients, tumor infiltrating Tregs express higher levels of OX40 than effector T cells (both CD4+ and CD8+) and peripheral Tregs (Lai et al., 2016; Marabelle et al., 2013b; Montler et al., 2016; Soroosh et al., 2007; Timperi et al., 2016) . Therefore, the secondary effects by which anti-OX40 antibodies trigger anti-tumor responses rely on their Fc-mediated effector functions in depleting intra-tumoral OX40+ Treg cells via antibody-dependent cytotoxicity (ADCC) and / or antibody-dependent cellular phagocytosis (ADCP) (Aspeslagh et al., 2016; Bulliard et al., 2014; Marabelle et al., 2013a; Marabelle et al., 2013b; Smyth et al., 2014) . This work demonstrates that agonistic anti-OX40 antibodies with Fc-mediated effector function could preferentially deplete intra-tumoral Tregs and improve the ratios of CD8+ effector T cells to Tregs in the tumor microenvironment (TME) , resulting in improved anti-tumor immune responses, increased tumor regression and improved survival (Bulliard et al., 2014; Carboni et al., 2003; Jacquemin et al., 2015; Marabelle et al., 2013b) . Based on these findings, there is an unmet medical need to develop agonistic anti-OX40 antibodies with both agonistic activities and Fc-mediated effector functions.
[0009] To date the agonistic anti-OX40 antibodies in the clinic are mostly ligand-competitive antibodies which block the OX40-OX40L interaction (e.g., WO2016196228A1) . Since OX40-OX40L interaction is essential for enhancing effective anti-tumor immunity, blockade of OX40-OX40L restricts the efficacy of these ligand-competitive antibodies. Therefore, OX40 agonist antibodies that specifically bind to OX40 while not interfering with OX40 interacting with OX40L have utility in the treatment of cancer and autoimmune disorders both as a monotherapy and in combination with other therapeutics, for example, an anti-PD1 antibody.
[0010] Monoclonal antibodies that target either PD1 or PDL1 can block this interaction and boost the immune response against cancer cells. These antibodies have been shown to be helpful in treating several types of cancer, including melanoma of the skin, non-small cell lung cancer (NSCLC) , kidney cancer, bladder cancer, head and neck cancers, and Hodgkin lymphoma. Cancer cells in most non-responders to single-agent checkpoint inhibitors escape through innate mechanisms that allow the cancer cells to grow and survive. As a result, disease progresses at a rate consistent with the natural history. However, unlike intrinsic resistance, late relapses are now emerging in patients with prior clinical benefit after longer follow-up of clinical trials, suggesting the emergence of acquired resistance (Jenkins et al., 2018) .SUMMARY
[0011] The present disclosure is directed to agonistic anti-OX40 antibodies and antigen-binding fragments thereof that activate OX40 and induce signaling in immune cells, thus promoting anti-tumor immunity in combination with an anti-PD1 antibody.
[0012] In one embodiment, the disclosure provides for agonistic monoclonal antibodies that bind to human OX40 or antigen-binding fragments thereof. In one aspect, the antibody of the present disclosure does not compete with OX40L or interfere with the binding of OX40 to its ligand OX40L.
[0013] In embodiments, a method of treating cancer includes administering to a subject an effective dose of a non-competitive anti-OX40 antibody or antigen-binding fragment thereof in combination with an anti-PD1 antibody or antigen binding fragment thereof.
[0014] In embodiments, the antibody or antigen-binding fragment thereof specifically binds to human OX40 and includes: a heavy chain variable region that includes (a) a HCDR (Heavy Chain Complementarity Determining Region) 1 of SEQ ID NO: 12, (b) a HCDR2 of SEQ ID NO: 13, and (c) a HCDR3 of SEQ ID NO: 14; and a light chain variable region that includes (d) a LCDR (Light Chain Complementarity Determining Region) 1 of SEQ ID NO: 15, (e) a LCDR2 of SEQ ID NO: 16, and (f) a LCDR3 of SEQ ID NO: 17, and the anti-PD1 antibody includes: a heavy chain variable region that includes (a) a HCDR1 of SEQ ID NO: 1, (b) a HCDR2 of SEQ ID NO: 2, and (c) a HCDR3 of SEQ ID NO: 3; and a light chain variable region that includes: (d) a LCDR1 of SEQ ID NO: 4, (e) a LCDR2 of SEQ ID NO: 5, and (f) a LCDR3 of SEQ ID NO: 6.
[0015] In embodiments, the anti-OX40 antibody or antigen-binding fragment thereof includes: a heavy chain variable region (VH) that includes SEQ ID NO: 18, and a light chain variable region (VL) that includes SEQ ID NO: 19; and the anti-PD1 antibody includes a heavy chain variable region (VH) that includes SEQ ID NO: 7, and a light chain variable region (VL) that includes SEQ ID NO: 8.
[0016] In embodiments, the anti-OX40 antibody or antigen-binding fragments thereof includes a heavy chain with an amino acid sequence shown as SEQ ID NO: 20, and a light chain with an amino acid sequence shown as SEQ ID NO: 21, and the anti-PD1 antibody or antigen-binding fragments thereof includes a heavy chain with an amino acid sequence shown as SEQ ID NO: 10, and a light chain with an amino acid sequence shown as SEQ ID NO: 11.
[0017] In embodiments, the cancer is selected from the group consisting of breast cancer, colon cancer, anal cancer, peritoneal cancer, bladder cancer, pancreatic cancer, head and neck cancer, gastric cancer, gastroesophageal junction cancer, kidney cancer, liver cancer, small cell lung cancer, non-small cell lung cancer, nasopharyngeal carcinoma, ovarian cancer, cervical cancer, endometrial cancer, uterine cancer, skin cancer, mesothelioma, lymphoma, leukemia, myeloma, and sarcoma.
[0018] In embodiments, the cancer is a metastatic cancer.
[0019] In embodiments, the treatment results in a sustained anti-cancer response in the subject after cessation of the treatment.
[0020] In one aspect, the anti-OX40 antibody or antigen binding fragment thereof is administered at a dosage from 20 mg –60 mg.
[0021] In another aspect, the anti-OX40 antibody or antigen binding fragment thereof is administered at a dosage from 20 mg –150 mg.
[0022] In another aspect, the anti-OX40 antibody or antigen binding fragment thereof is administered at a dosage from 20 mg –300 mg.
[0023] In yet another aspect, the anti-OX40 antibody or antigen binding fragment thereof is administered at a dosage from 20 mg –600 mg.
[0024] In still another aspect, the anti-OX40 antibody or antigen binding fragment thereof is administered at a dosage from 20 mg –1200 mg.
[0025] In another aspect, the anti-OX40 antibody or antigen binding fragment thereof is administered at a dosage from 20 mg –2400 mg.
[0026] In another aspect, the anti-OX40 antibody or antigen binding fragment thereof is administered at a dosage from 20 mg –3600 mg.
[0027] In other aspects, the anti-OX40 antibody or antigen binding fragment thereof is administered at a dosage from 300 mg –600 mg, 300 mg –1200 mg, 300 mg –2400 mg, or 300 mg –3600 mg.
[0028] In other aspects, the anti-OX40 antibody or antigen binding fragment thereof is administered at a dosage from 600 mg –1200 mg, 600 mg –2400 mg, or 600 mg –3600 mg.
[0029] In another aspect, the anti-OX40 antibody or antigen binding fragment thereof is administered at a dosage of 20 mg.
[0030] In another aspect, the anti-OX40 antibody or antigen binding fragment thereof is administered at a dosage of 60 mg.
[0031] In another aspect, the anti-OX40 antibody or antigen binding fragment thereof is administered at a dosage of 150 mg.
[0032] In yet another aspect, the anti-OX40 antibody or antigen binding fragment thereof is administered at a dosage of 300 mg.
[0033] In still another aspect, the anti-OX40 antibody or antigen binding fragment thereof is administered at a dosage of 600 mg.
[0034] In another aspect, the anti-OX40 antibody or antigen binding fragment thereof is administered at a dosage of 1200 mg.
[0035] In another aspect, the anti-OX40 antibody or antigen binding fragment thereof is administered at a dosage of 2400 mg.
[0036] In another aspect, the anti-OX40 antibody or antigen binding fragment thereof is administered at a dosage of 3600 mg.
[0037] In another aspect, the anti-PD1 antibody or antigen binding fragment thereof is administered at a dosage of 200 mg.
[0038] In yet another aspect, the anti-OX40 antibody or antigen binding fragment thereof is administered once a week.
[0039] In another aspect, the anti-OX40 antibody or antigen binding fragment thereof is administered twice a week.
[0040] In another aspect, the anti-OX40 antibody or antigen binding fragment thereof is administered three times a week.
[0041] In still another aspect, the anti-OX40 antibody or antigen binding fragment thereof is administered once every two weeks.
[0042] In another aspect, the anti-OX40 antibody or antigen binding fragment thereof is administered once every three weeks.
[0043] In another aspect, the anti-OX40 antibody or antigen binding fragment thereof is administered once a month.
[0044] In another aspect, the anti-PD1 antibody or antigen binding fragment thereof is administered once every three weeks.
[0045] In embodiments, the anti-OX40 antibody of the present disclosure is of IgG1, IgG2, IgG3, or IgG4 isotype. In one embodiment, the antibody of the present disclosure includes an Fc domain of wild-type human IgG1 (also referred as human IgG1wt or huIgG1) or IgG2. In another embodiment, the antibody of the present disclosure includes an Fc domain of human IgG4 with S228P and / or R409K substitutions (according to EU numbering system) .
[0046] In one embodiment, the anti-OX40 antibody of the present disclosure binds to OX40 with a binding affinity (KD) of from 1 x 10-6 M to 1 x 10-10 M. In another embodiment, the antibody of the present disclosure binds to OX40 with a binding affinity (KD) of about 1 x 10-6 M, about 1 x 10-7 M, about 1 x 10-8 M, about 1 x 10-9 M, or about 1 x 10-10 M.
[0047] In another embodiment, the anti-OX40 antibody of the present disclosure shows a cross-species binding activity to cynomolgus OX40.
[0048] In one embodiment, the anti-OX40 antibody of the present disclosure binds to an epitope of human OX40 outside of the OX40-OX40L interaction interface. In another embodiment, the anti-OX40 antibody of the present disclosure does not compete with OX40 ligand binding to OX40. In yet another embodiment, the anti-OX40 antibody of the present disclosure does not block the interaction between OX40 and its ligand OX40L.
[0049] In embodiments, anti-OX40 antibodies of the present disclosure are agonistic and significantly enhance the immune response. In an embodiment, the antibody of the present disclosure can significantly stimulate primary T cells to produce IL-2 in a mixed lymphocyte reaction (MLR) assay.
[0050] In one embodiment, anti-OX40 antibodies of the present disclosure have strong Fc-mediated effector functions. In embodiments, the antibodies mediate antibody-dependent cellular cytotoxicity (ADCC) against OX40Hi target cells such as regulatory T cells (Treg cells) by NK cells. In one aspect, the disclosure provides a method of evaluating the anti-OX40 antibody-mediated in vitro depletion of specific T-cell subsets based on different OX40 expression levels.
[0051] In embodiments, anti-OX40 antibodies or antigen-binding fragments of the present disclosure do not block the OX40-OX40L interaction. In embodiments, the anti-OX40 antibodies exhibit dose-dependent anti-tumor activity in vivo, as shown in animal models. The dose-dependent activity may be differentiated from the activity profile of anti-OX40 antibodies that block OX40-OX40L interaction.
[0052] In yet another aspect, the present disclosure relates to a method of treating a disease in a subject, which includes administering the anti-OX40 antibody or antigen-binding fragment thereof, or an anti-OX40 antibody pharmaceutical composition in a therapeutically effective amount to a subject in need thereof. In another embodiment, the disease to be treated by the antibody or the antigen-binding fragment is cancer or an autoimmune disease.
[0053] The still another aspect, the present disclosure relates to use of the anti-OX40 antibody or antigen-binding fragment thereof, or a pharmaceutical composition including the antibody, in combination with an anti-PD1 antibody for treating a disease, such as cancer or autoimmune diseases.BRIEF DESCRIPTION OF THE DRAWINGS
[0054] Figure 1A shows BGB-A445 anti-tumor activity in an MC38 syngeneic tumor model.
[0055] Figure 1B shows anti-tumor activity of a reference anti-OX40 antibody in an MC38 syngeneic tumor model.
[0056] Figure 1C shows a comparison of tumor growth inhibition (TGI) by BGB-A445 and an anti-OX40 reference antibody.
[0057] Figure 2 shows the activity of BGB-A445 in combination with an anti-PD-1 antibody, BGB-A317, in a mouse model.
[0058] Figure 3A shows the amount of IL-2 release in vitro by BGB-A445 administration in comparison with an anti-OX40 reference antibody. Figure 3B shows the level of IL-2 release of BGB-A445 in comparison with an anti-OX40 reference antibody, either with or without blocking the OX40 receptor with OX40 ligand. Figure 3C and Figure 3D show the mean fluorescence intensity (MFI) of either CD83 (Figure 3C) or CD86 (Figure 3D) on dendritic cells in the presence of BGB-A445 or a reference anti-OX40 antibody.
[0059] Figure 4 is a graphic of the BGB-A445 dosing used in a clinical study.
[0060] Figures 5A-5F are tables of the demographics and baseline characteristics of patients enrolled in the study of Figure 4. Figures 5A and 5B include data from Part A of the study as of April 30, 2023. Figures 5C-5F include data from Part A (Figures 5C and 5D) and Part B (Figures 5E and 5F) as of March 1, 2024.
[0061] Figures 6A-6F are tables showing the treatment-emergent adverse events (TEAEs) involved with the administration of BGB-A445 in the study of Figure 4 as of August 31, 2022 (Figures 6A and 6B) , April 30, 2023 (Figures 6C and 6D) , or March 1, 2024 (Figures 6E and 6F) .
[0062] Figures 7A-7D are plots showing the duration of treatment and response for Part A (Figures 7A and 7C) and Part B (Figures 7B and 7D) of the study of Figure 4 as of April 30, 2023 (Figures 7A and 7B) , or March 1, 2024 (Figures 7C and 7D) .
[0063] Figures 8A-8D are plots showing the best response in a target lesion for Part A (Figures 8A and 8C) and Part B (Figures 8B and 8D) of the study of Figure 4 as of April 30, 2023 (Figures 8A and 8B) or March 1, 2024 (Figures 8C and 8D) .
[0064] Figures 9A-9C show serum PK profiles of BGB-A445 from the study of Figure 4 as of January 28, 2022 (Figure 9A) or October 16, 2023 (Figures 9B and 9C) .
[0065] Figures 10A and 10B show OX40 receptor occupancy on peripheral CD4+ T cells in BGB-A445 monotherapy (Figure 10A) and combination therapy (Figure 10B) across doses.
[0066] Figure 11 shows soluble OX40 in BGB-A445 monotherapy across doses.
[0067] Figure 12 shows soluble OX40 in BGB-A445 combination therapy across doses.
[0068] Definitions
[0069] In the present disclosure, the following terms have the following meanings unless indicated otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art to which this disclosure pertains. In the event that there is a plurality of definitions for a term provided herein, these Definitions prevail unless stated otherwise.
[0070] As used herein, including in the appended claims, the singular forms of words such as “a, ” “an, ” and “the” include their corresponding plural references unless the context clearly dictates otherwise.
[0071] The term “or” is used to mean, and is used interchangeably with, the term “and / or” unless the context clearly dictates otherwise.
[0072] Unless specifically stated or evident from context, as used herein, the term “about” refers to a value or composition that is within an acceptable error range for the particular value or composition as determined by one of ordinary skill in the art, which will depend in part on how the value or composition is measured or determined, i.e., the limitations of the measurement system. For example, “about” can mean within one or more than one standard deviation per the practice in the art. “About” can mean a range of up to 10% (i.e., ±10%) . Thus, “about” can be understood to be within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, 0.01%, or 0.001%greater or less than the stated value. For example, about 5 mg can include any amount between 4.5 mg and 5.5 mg. Furthermore, particularly with respect to biological systems or processes, the terms can mean up to an order of magnitude or up to 5-fold of a value. When particular values or compositions are provided in the instant disclosure, unless otherwise stated, the meaning of “about” should be assumed to be within an acceptable error range for that particular value or composition.
[0073] The term “OX40” refers to an approximately 50 kDa type I transmembrane glycoprotein, a member of tumor necrosis factor receptor super family. OX40 is also known as ACT35, CD134, or TNFRSF4. The amino acid sequence of human OX40 can also be found at accession number NP_003318 and the nucleotide sequence encoding the OX40 protein has accession number X75962.1. The term “OX40 ligand” or “OX40L” refers to the sole ligand of OX40 and is interchangeable with gp34, CD252, or TNFSF4.
[0074] The terms “administration, ” and “administering, ” as used herein, when applied to an animal, human, subject, cell, tissue, organ, or biological fluid, means contact of an exogenous pharmaceutical, therapeutic, diagnostic agent, or composition to the animal, human, subject, cell, tissue, organ, or biological fluid. Treatment of a cell encompasses contact of a reagent to the cell, as well as contact of a reagent to a fluid, where the fluid is in contact with the cell.
[0075] The term “subject” or “patient” herein includes any organism, preferably an animal, more preferably a mammal (e.g., rat, mouse, dog, cat, rabbit, primate) and most preferably a human (e.g., a patient comprising, or at risk of having, a disorder described herein) .
[0076] “Treating” any disease or disorder refers in one aspect to ameliorating the disease or disorder (i.e., slowing or arresting or reducing the development of the disease or at least one of the clinical symptoms thereof) . In another aspect, “treat, ” “treating, ” or “treatment” refers to alleviating or ameliorating at least one physical parameter including those which may not be discernible by the patient. In yet another aspect, “treat, ” “treating, ” or “treatment” refers to modulating the disease or disorder, either physically (e.g., stabilization of a discernible symptom) , physiologically (e.g., stabilization of a physical parameter) , or both.
[0077] The term “affinity” as used herein refers to the strength of interaction between antibody and antigen. Within the antigen, the variable regions of the antibody interact through non-covalent forces with the antigen at numerous sites. In general, the more interactions, the stronger the affinity.
[0078] The term “antibody, ” ( “Ab") , as used herein refers to a polypeptide of the immunoglobulin family that can bind a corresponding antigen non-covalently, reversibly, and in a specific manner. For example, a naturally occurring IgG antibody is a tetramer comprising at least two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds. Each heavy chain is comprised of a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region. The heavy chain constant region is comprised of three domains, CH1, CH2 and CH3. Each light chain is comprised of a light chain variable region (abbreviated herein as VL or Vκ) and a light chain constant region. The light chain constant region is comprised of one domain, CL. The VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs) , interspersed with regions that are more conserved, termed framework regions (FR) . Each VH and VL is composed of three CDRs and four framework regions (FRs) arranged from amino-terminus to carboxyl-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. The variable regions of the heavy and light chains contain a binding domain that interacts with an antigen. The constant regions of the antibodies can mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (Clq) of the classical complement system.
[0079] The positions of the CDRs and framework regions can be determined using various well known definitions in the art, e.g., Kabat, Chothia, AbM and IMGT (see, e.g., Johnson et al., Nucleic Acids Res., 29: 205-206 (2001) ; Chothia and Lesk, J. Mol. Biol., 196: 901-917 (1987) ; Chothia et al., Nature, 342: 877-883 (1989) ; Chothia et al., J. Mol. Biol., 227: 799-817 (1992) ; Al-Lazikani et al., J. Mol. Biol., 273: 927-748 (1997) ; Lefranc, M. -P., The Immunologist, 7, 132-136 (1999) ; Lefranc, M. -P. et al., Dev. Comp. Immunol., 27, 55-77 (2003) ) .
[0080] The term “antibody” includes, but is not limited to, monoclonal antibodies, human antibodies, humanized antibodies, chimeric antibodies, anti-idiotypic (anti-Id) antibodies, and human engineered antibodies. The antibodies can be of any isotype / class (e.g., IgG, IgE, IgM, IgD, IgA and IgY) , or subclass (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) .
[0081] The term “monoclonal antibody” or “mAb” or “Mab” herein means a population of substantially homogeneous antibodies, i.e., the antibody molecules in the population are identical in amino acid sequence except for possible naturally occurring mutations that can be present in minor amounts. In contrast, conventional (polyclonal) antibody preparations typically include a multitude of different antibodies having different amino acid sequences in their variable domains, particularly their CDRs, which are often specific for different epitopes. The modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies and is not to be construed as requiring production of the antibody by any particular method. Monoclonal antibodies (mAbs) can be obtained by methods known to those skilled in the art. See, for example Kohler et al., Nature 1975 256: 495-497; U.S. Pat. No. 4,376,110; Ausubel et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY 1992; Harlow et al., ANTIBODIES: A LABORATORY MANUAL, Cold spring Harbor Laboratory 1988; and Colligan et al., CURRENT PROTOCOLS IN IMMUNOLOGY 1993.
[0082] In general, the basic antibody structural unit comprises a tetramer. Each tetramer includes two identical pairs of polypeptide chains, each pair having one “light chain” (about 25 kDa) and one “heavy chain” (about 50-70 kDa) . The amino-terminal portion of each chain includes a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The carboxy-terminal portion of the heavy chain can define a constant region primarily responsible for effector function. Typically, human light chains are classified as kappa and lambda light chains. Furthermore, human heavy chains are typically classified as α, δ, ε, γ, or μ, and define the antibody's isotypes as IgA, IgD, IgE, IgG, and IgM, respectively.
[0083] Within light and heavy chains, the variable and constant regions are joined by a “J” region of about 12 or more amino acids, with the heavy chain also including a “D” region of about 10 more amino acids.
[0084] The variable regions of each light / heavy chain (VL / VH) pair form the antibody binding site. Thus, in general, an intact antibody has two binding sites. Except in bifunctional or bispecific antibodies, the two binding sites are, in general, the same in primary sequence.
[0085] Typically, the variable domains of both the heavy and light chains comprise three hypervariable regions, also called “complementarity determining regions (CDRs) , ” which are located between relatively conserved framework regions (FR) . The CDRs are usually aligned by the framework regions, enabling binding to a specific epitope. In general, from N-terminal to C-terminal, both light and heavy chain variable domains comprise FR-1 (or FR1) , CDR-1 (or CDR1) , FR-2 (FR2) , CDR-2 (CDR2) , FR-3 (FR3) , CDR-3 (CDR3) , and FR-4 (FR4) . The positions of the CDRs and framework regions can be determined using various well known definitions in the art, e.g., Kabat, Chothia, AbM, and IMGT (see, e.g., Johnson et al., Nucleic Acids Res., 29: 205-206 (2001) ; Chothia and Lesk, J. Mol. Biol., 196: 901-917 (1987) ; Chothia et al., Nature, 342: 877-883 (1989) ; Chothia et al., J. Mol. Biol., 227: 799-817 (1992) ; Al-Lazikani et al., J. Mol. Biol., 273: 927-748 (1997) ImMunoGenTics (IMGT) numbering (Lefranc, M. -P., The Immunologist, 7, 132-136 (1999) ; Lefranc, M. -P. et al., Dev. Comp. Immunol., 27, 55-77 (2003) ( “IMGT” numbering scheme) ) . Definitions of antigen combining sites are also described in the following: Ruiz et al., Nucleic Acids Res., 28: 219-221 (2000) ; and Lefranc, M.P., Nucleic Acids Res., 29: 207-209 (2001) ; MacCallum et al., J. Mol. Biol., 262: 732-745 (1996) ; and Martin et al., Proc. Natl. Acad. Sci. USA, 86: 9268-9272 (1989) ; Martin et al., Methods Enzymol., 203: 121-153 (1991) ; and Rees et al., In Sternberg M.J.E. (ed. ) , Protein Structure Prediction, Oxford University Press, Oxford, 141-172 (1996) . For example, under Kabat, the CDR amino acid residues in the heavy chain variable domain (VH) are numbered 31-35 (HCDR1) , 50-65 (HCDR2) , and 95-102 (HCDR3) ; and the CDR amino acid residues in the light chain variable domain (VL) are numbered 24-34 (LCDR1) , 50-56 (LCDR2) , and 89-97 (LCDR3) . Under Chothia the CDR amino acids in the VH are numbered 26-32 (HCDR1) , 52-56 (HCDR2) , and 95-102 (HCDR3) ; and the amino acid residues in VL are numbered 26-32 (LCDR1) , 50-52 (LCDR2) , and 91-96 (LCDR3) . By combining the CDR definitions of both Kabat and Chothia, the CDRs consist of amino acid residues 26-35 (HCDR1) , 50-65 (HCDR2) , and 95-102 (HCDR3) in human VH and amino acid residues 24-34 (LCDR1) , 50-56 (LCDR2) , and 89-97 (LCDR3) in human VL. Under IMGT the CDR amino acid residues in the VH are numbered approximately 26-35 (HCDR1) , 51-57 (HCDR2) , and 93-102 (HCDR3) , and the CDR amino acid residues in the VL are numbered approximately 27-32 (LCDR1) , 50-52 (LCDR2) , and 89-97 (LCDR3) (numbering according to Kabat) . Under IMGT, the CDR regions of an antibody can be determined using the program IMGT / DomainGap Align
[0086] The term “hypervariable region” means the amino acid residues of an antibody that are responsible for antigen-binding. The hypervariable region comprises amino acid residues from a “CDR” (e.g., LCDR1, LCDR2, and LCDR3 in the light chain variable domain and HCDR1, HCDR2, and HCDR3 in the heavy chain variable domain) . See, Kabat et al., (1991) Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (defining the CDR regions of an antibody by sequence) ; see also Chothia and Lesk (1987) J. Mol. Biol. 196: 901-917 (defining the CDR regions of an antibody by structure) . The term “framework” or “FR” residues means those variable domain residues other than the hypervariable region residues defined herein as CDR residues.
[0087] Unless otherwise indicated, an “antigen-binding fragment” means antigen-binding fragments of antibodies, i.e., antibody fragments that retain the ability to bind specifically to the antigen bound by the full-length antibody, e.g., fragments that retain one or more CDR regions. Examples of antigen-binding fragments include, but are not limited to, Fab, Fab', F (ab') 2, and Fv fragments; diabodies; linear antibodies; single-chain antibody molecules, e.g., single chain Fv (ScFv) ; nanobodies (or VHH antibody) ; and multi-specific antibodies formed from antibody fragments.
[0088] As used herein, an antibody or antigen-binding antibody fragment “specifically binds” to an antigen (e.g., a protein) , meaning the antibody exhibits preferential binding to that target as compared to other proteins, but this specificity does not require absolute binding specificity. A “specific” or “selective” binding reaction is determinative of the presence of the antigen in a heterogeneous population of proteins and other biologics, for example, in a biological sample, blood, serum, plasma or tissue sample. Thus, under certain designated immunoassay conditions, the antibodies or antigen-binding fragments thereof specifically bind to a particular antigen at least two times greater when compared to the background level and do not specifically bind in a significant amount to other antigens present in the sample. In one aspect, under designated immunoassay conditions, the antibody or antigen-binding fragment thereof specifically binds to a particular antigen at least ten times when compared to the background level of binding and does not specifically bind in a significant amount to other antigens present in the sample.
[0089] The term “human antibody” herein means an antibody that comprises only human immunoglobulin protein sequences. A human antibody can contain murine carbohydrate chains if produced in a mouse, in a mouse cell, or in a hybridoma derived from a mouse cell. Similarly, “mouse antibody” or “rat antibody” mean an antibody that comprises only mouse or rat immunoglobulin protein sequences, respectively.
[0090] The term “humanized” or “humanized antibody” means forms of antibodies that contain sequences from non-human (e.g., murine, rabbit, llama, etc. ) antibodies as well as human antibodies. Such antibodies contain minimal sequence derived from non-human immunoglobulin. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin sequence. The humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc) , typically that of a human immunoglobulin. The prefix “hum, ” “hu, ” “Hu, ” or “h” is added to antibody clone designations when necessary to distinguish humanized antibodies from parental (e.g., rodent) antibodies. The humanized forms of rodent antibodies will generally comprise the same CDR sequences of the parental rodent antibodies, although certain amino acid substitutions can be included to increase affinity, increase stability of the humanized antibody, remove a post-translational modification or for other reasons.
[0091] As used herein, the term “non-competitive” means that antibody binding occurs and does not interfere with ligand binding to the receptor.
[0092] The term “corresponding human germline sequence” refers to the nucleic acid sequence encoding a human variable region amino acid sequence or subsequence that shares the highest determined amino acid sequence identity with a reference variable region amino acid sequence or subsequence in comparison to all other known variable region amino acid sequences encoded by human germline immunoglobulin variable region sequences. The corresponding human germline sequence can also refer to the human variable region amino acid sequence or subsequence with the highest amino acid sequence identity with a reference variable region amino acid sequence or subsequence in comparison to all other evaluated variable region amino acid sequences. The corresponding human germline sequence can be framework regions only, complementarity determining regions only, framework and complementary determining regions, a variable region, or other combinations of sequences or subsequences. Sequence identity can be determined using the methods described herein, for example, aligning two sequences using BLAST, ALIGN, or another alignment algorithm known in the art. The corresponding human germline nucleic acid or amino acid sequence can have at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%sequence identity with the reference variable region nucleic acid or amino acid sequence. In addition, if the antibody contains a constant region, the constant region also is derived from such human sequences, e.g., human germline sequences, or mutated versions of human germline sequences or antibody containing consensus framework sequences derived from human framework sequences analysis, for example, as described in Knappik et al., J. Mol. Biol. 296: 57-86, 2000.
[0093] The term “equilibrium dissociation constant” or “KD” or “M” refers to the dissociation rate constant (kd, time-1) divided by the association rate constant (ka, time-1, M-l) . Equilibrium dissociation constants can be measured using any known method in the art. The antibodies of the present disclosure generally will have an equilibrium dissociation constant of less than about 10-7 or 10-8 M, for example, less than about 10-9 M or 10-10 M, in some aspects, less than about 10-11 M, 10-12 M or 10-13 M.
[0094] The term “cancer” or “tumor” used herein has the broadest meaning as understood in the art and refers to the physiological condition in mammals that is typically characterized by unregulated cell growth. In the context of the present disclosure, the cancer is not limited to a certain type or location. The cancer may be metastatic.
[0095] In the context of the present disclosure, when reference is made to an amino acid sequence, the term “conservative substitution” means substitution of the original amino acid by a new amino acid that does not substantially alter the chemical, physical and / or functional properties of the antibody or fragment, e.g., its binding affinity to OX40. Common conservative substations of amino acids are well known in the art.
[0096] Examples of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST algorithms, which are described in Altschul et al., Nuc. Acids Res. 25: 3389-3402, 1977; and Altschul et al., J. Mol. Biol. 215: 403-410, 1990. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information. This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold. These initial neighborhood word hits act as values for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues; always < 0) . For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a word length (W) of 11, an expectation (E) of 10, M=5, N=-4, and a comparison of both strands. For amino acid sequences, the BLAST program uses as defaults a word length of 3, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff and Henikoff, (1989) Proc. Natl. Acad. Sci. USA 89: 10915) , alignments (B) of 50, M=5, N=-4, and a comparison of both strands.
[0097] The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin and Altschul, Proc. Natl. Acad. Sci. USA 90: 5873-5787, 1993) . One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P (N) ) , which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.2, more preferably less than about 0.01, and most preferably less than about 0.001.
[0098] The percent identity between two amino acid sequences can also be determined using the algorithm of E. Meyers and W. Miller, Comput. Appl. Biosci. 4: 11-17, (1988) , which has been incorporated into the ALIGN program (version 2.0) , using a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4. In addition, the percent identity between two amino acid sequences can be determined using the Needleman and Wunsch, J. Mol. Biol. 48: 444-453, (1970) , algorithm which has been incorporated into the GAP program in the GCG software package using either a BLOSUM62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6.
[0099] The term “nucleic acid” is used herein interchangeably with the term “polynucleotide” and refers to deoxyribonucleotides or ribonucleotides and polymers thereof in either single-or double-stranded form. The term encompasses nucleic acids containing known nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, and non-naturally occurring, which have similar binding properties as the reference nucleic acid, and which are metabolized in a manner similar to the reference nucleotides. Examples of such analogs include, without limitation, phosphorothioates, phosphoramidates, methyl phosphonates, chiral-methyl phosphonates, 2-O-methyl ribonucleotides, peptide-nucleic acids (PNAs) .
[0100] The term “operably linked” in the context of nucleic acids refers to a functional relationship between two or more polynucleotide (e.g., DNA) segments. Typically, it refers to the functional relationship of a transcriptional regulatory sequence to a transcribed sequence. For example, a promoter or enhancer sequence is operably linked to a coding sequence if it stimulates or modulates the transcription of the coding sequence in an appropriate host cell or other expression system. Generally, promoter transcriptional regulatory sequences that are operably linked to a transcribed sequence are physically contiguous to the transcribed sequence, i.e., they are cis-acting. However, some transcriptional regulatory sequences, such as enhancers, need not be physically contiguous or located in close proximity to the coding sequences whose transcription they enhance.
[0101] In some aspects, the present disclosure provides compositions, e.g., pharmaceutically acceptable compositions, which include anti-OX40 antibodies as described herein, formulated together with at least one pharmaceutically acceptable excipient. As used herein, the term “pharmaceutically acceptable excipient” includes any and all solvents, dispersion media, isotonic and absorption delaying agents, and the like that are physiologically compatible. The excipient can be suitable for intravenous, intramuscular, subcutaneous, parenteral, rectal, spinal or epidermal administration (e.g., by injection or infusion) .
[0102] The compositions disclosed herein can be in a variety of forms. These include, for example, liquid, semi-solid and solid dosage forms, such as liquid solutions (e.g., injectable and infusion solutions) , dispersions or suspensions, liposomes, and suppositories. A suitable form depends on the intended mode of administration and therapeutic application. One suitable mode of administration is parenteral (e.g., intravenous, subcutaneous, intraperitoneal, intramuscular) . In some embodiments, the antibody is administered by intravenous infusion or injection. In certain embodiments, the antibody is administered by intramuscular or subcutaneous injection.
[0103] The term “therapeutically effective amount” as herein used, refers to the amount of an antibody that, when administered to a subject for treating a disease, or at least one of the clinical symptoms of a disease or disorder, is sufficient to effect such treatment for the disease, disorder, or symptom. The “therapeutically effective amount” can vary with the antibody, the disease, disorder, and / or symptoms of the disease or disorder, severity of the disease, disorder, and / or symptoms of the disease or disorder, the age of the subject to be treated, and / or the weight of the subject to be treated. An appropriate amount in any given instance can be apparent to those skilled in the art or can be determined by routine experiments. In the case of combination therapy, the “therapeutically effective amount” refers to the total amount of the combination components.
[0104] The term “combination therapy” refers to the administration of two or more therapeutic agents to treat a therapeutic condition or disorder. Such administration encompasses co-administration of these therapeutic agents in a substantially simultaneous manner. Such administration also encompasses co-administration in multiple or in separate containers or formulations (e.g., capsules, powders, and liquids) for each active ingredient. Powders and / or liquids can be reconstituted or diluted to a desired dose prior to administration. In addition, “combination therapy” encompasses use of each type of therapeutic agent in a sequential manner, either at approximately the same time or at different times. In either case, the treatment regimen will provide beneficial effects of the drug combination in treating the conditions or disorders described herein.
[0105] As used herein, the phrase “in combination with” means that an anti-OX40 antibody is administered to a subject at the same time as, before, or after administration of an anti-PD1 antibody. In certain embodiments, the anti-PD1 antibody is administered as a co-formulation with the anti-OX40 antibody.DETAILED DESCRIPTION
[0106] According to the present disclosure, an anti-OX40 antibody in combination with an anti-PD1 antibody inhibits tumor growth. Such inhibition may be greater than treatment with either antibody alone.
[0107] Anti-PD1 antibodies
[0108] The present disclosure provides for anti-PD1 antibodies disclosed, for example, in US Patent No. 8,735,553. Amino acid sequences of the same are provided in Table 1 below.
[0109] Table 1
[0110] Anti-OX40 antibodies
[0111] The present disclosure provides for antibodies and antigen-binding fragments that specifically bind human OX40. The present disclosure provides anti-OX40 antibodies that have desirable pharmacokinetic characteristics and other desirable attributes, and thus can be used for reducing the likelihood of or treating cancer. The present disclosure further provides pharmaceutical compositions comprising the antibodies and methods of making and using such pharmaceutical compositions for the prevention and treatment of cancer and associated disorders.
[0112] The present disclosure provides for antibodies or antigen-binding fragments thereof that specifically bind to OX40. In some embodiments, the anti-OX40 antibodies comprise at least one antigen-binding site or at least a variable region. In some embodiments, the anti-OX40 antibodies comprise an antigen-binding fragment from an OX40 antibody described herein. In some embodiments, the anti-OX40 antibody is isolated or recombinant. Antibodies or antigen-binding fragments of the present disclosure include, but are not limited to, the antibodies or antigen-binding fragments thereof described in Table 2 below.
[0113] Table 2
[0114] Further Alteration of the Framework of Fc Region
[0115] In aspects, the Fc region is altered by replacing at least one amino acid residue with a different amino acid residue to alter the effector functions of the antibody. For example, one or more amino acids can be replaced with a different amino acid residue such that the antibody has an altered affinity for an effector ligand but retains the antigen-binding ability of the parent antibody. The effector ligand to which affinity is altered can be, for example, an Fc receptor or the C1 component of complement. This approach is described in, e.g., U.S. Pat. Nos. 5,624,821 and 5,648,260, both by Winter et al.
[0116] In another aspect, one or more amino acid residues can be replaced with one or more different amino acid residues such that the antibody has altered C1q binding and / or reduced or abolished complement dependent cytotoxicity (CDC) . This approach is described in, e.g., U.S. Pat. No. 6,194,551 by Idusogie et al.
[0117] In yet another aspect, one or more amino acid residues are changed to thereby alter the ability of the antibody to fix complement. This approach is described in, e.g., the publication WO 94 / 29351 by Bodmer et al. In a specific aspect, one or more amino acids of an antibody or antigen-binding fragment thereof of the present disclosure are replaced by one or more allotypic amino acid residues for the IgG1 subclass and the kappa isotype. Allotypic amino acid residues also include, but are not limited to, the constant region of the heavy chain of the IgG1, IgG2, and IgG3 subclasses as well as the constant region of the light chain of the kappa isotype as described by Jefferis et al., MAbs. 1: 332-338 (2009) .
[0118] In another aspect, the Fc region is modified to increase the ability of the antibody to mediate antibody dependent cellular cytotoxicity (ADCC) and / or to increase the affinity of the antibody for an Fcγ receptor by modifying one or more amino acids. This approach is described in, e.g., the publication WO00 / 42072 by Presta. Moreover, the binding sites on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn have been mapped and variants with improved binding have been described (see Shields et al., J. Biol. Chem. 276: 6591-6604, 2001) .
[0119] In still another aspect, the glycosylation of the antibody is modified. For example, an aglycosylated antibody can be made (i.e., the antibody lacks or has reduced glycosylation) . Glycosylation can be altered to, for example, increase the affinity of the antibody for “antigen. ” Such carbohydrate modifications can be accomplished by, for example, altering one or more sites of glycosylation within the antibody sequence. For example, one or more amino acid substitutions can be made that result in elimination of one or more variable region framework glycosylation sites to thereby eliminate glycosylation at that site. Such aglycosylation can increase the affinity of the antibody for an antigen. Such an approach is described in, e.g., U.S. Pat. Nos. 5,714,350 and 6,350,861 by Co et al.
[0120] Additionally, or alternatively, an antibody can be made that has an altered type of glycosylation, such as a hypofucosylated antibody having reduced amounts of fucosyl residues or an antibody having increased bisecting GlcNac structures. Such altered glycosylation patterns have been demonstrated to increase the ADCC ability of antibodies. Such carbohydrate modifications can be accomplished by, for example, expressing the antibody in a host cell with an altered glycosylation pathway. Cells with altered glycosylation pathways have been described in the art and can be used as host cells in which to express recombinant antibodies to thereby produce an antibody with altered glycosylation. For example, EP 1,176,195 by Hang et al. describes a cell line with a functionally disrupted FUT8 gene, which encodes a fucosyl transferase, such that antibodies expressed in such a cell line exhibit hypofucosylation. Publication WO 03 / 035835 by Presta describes a variant CHO cell line, Lecl3 cells, with reduced ability to attach fucose to Asn (297) -linked carbohydrates, also resulting in hypofucosylation of antibodies expressed in that host cell (see also Shields et al., (2002) J. Biol. Chem. 277: 26733-26740) . WO99 / 54342 by Umana et al. describes cell lines engineered to express glycoprotein-modifying glycosyl transferases (e.g., beta (1, 4) -N acetylglucosaminyltransferase III (GnTIII) ) such that antibodies expressed in the engineered cell lines exhibit increased bisecting GlcNac structures, which results in increased ADCC activity of the antibodies (see also Umana et al., Nat. Biotech. 17: 176-180, 1999) .
[0121] In another aspect, if a reduction of ADCC is desired, human antibody subclass IgG4 was shown in many previous reports to have only modest ADCC and almost no CDC effector function (Moore G L, et al., 2010 MAbs, 2: 181-189) . However, natural IgG4 was found less stable in stress conditions such as in acidic buffer or under increasing temperature (Angal, S. 1993 Mol Immunol, 30: 105-108; Dall'Acqua, W. et al., 1998 Biochemistry, 37: 9266-9273; Aalberse et al., 2002 Immunol, 105: 9-19) . Reduced ADCC can be achieved by operably linking the antibody to an IgG4 Fc engineered with combinations of alterations that reduce FcγR binding or C1q binding activities, thereby reducing or eliminating ADCC and CDC effector functions. Considering the physicochemical properties of an antibody as a biological drug, one of the less desirable, intrinsic properties of IgG4 is dynamic separation of its two heavy chains in solution to form half antibody, which lead to bi-specific antibodies generated in vivo via a process called “Fab arm exchange” (Van der Neut Kolfschoten M, et al., 2007 Science, 317: 1554-157) . The mutation of serine to proline at position 228 (EU numbering system) appeared inhibitory to the IgG4 heavy chain separation (Angal, S. 1993 Mol Immunol, 30: 105-108; Aalberse et al., 2002 Immunol, 105: 9-19) . Some of the amino acid residues in the hinge and γFc region were reported to have impact on antibody interaction with Fcγ receptors (Chappel S M, et al., 1991 Proc. Natl. Acad. Sci. USA, 88: 9036-9040; Mukherjee, J. et al., 1995 FASEB J, 9: 115-119; Armour, K.L. et al., 1999 Eur J Immunol, 29: 2613-2624; Clynes, R.A. et al, 2000 Nature Medicine, 6: 443-446; Arnold J.N., 2007 Annu Rev Immunol, 25: 21-50) . Furthermore, some rarely occurring IgG4 isoforms in human population can also elicit different physicochemical properties (Brusco, A. et al., 1998 Eur J Immunogenet, 25: 349-55; Aalberse et al., 2002 Immunol, 105: 9-19) . To generate antibodies with low ADCC and CDC but with good stability, it is possible to modify the hinge and Fc region of human IgG4 and introduce a number of alterations. These modified IgG4 Fc molecules can be found in SEQ ID NOs: 83-88, U.S. Patent No. 8,735,553 to Li et al.
[0122] Antibody Production
[0123] Antibodies and antigen-binding fragments thereof can be produced by any means known in the art, including but not limited to, recombinant expression, chemical synthesis, and enzymatic digestion of antibody tetramers, whereas full-length monoclonal antibodies can be obtained by, e.g., hybridoma or recombinant production.
[0124] A hybridoma producing a monoclonal antibody can be cultivated in vitro or in vivo. High titers of monoclonal antibodies can be obtained in in vivo production where cells from the individual hybridomas are injected intraperitoneally into mice, such as pristine-primed Balb / c mice to produce ascites fluid containing high concentrations of the desired antibodies. Monoclonal antibodies of isotype IgM or IgG can be purified from such ascites fluids, or from culture supernatants, using column chromatography methods well known to those of skill in the art.
[0125] Recombinant expression can be from any appropriate host cells known in the art, for example, mammalian host cells, bacterial host cells, yeast host cells, insect host cells, etc.
[0126] The present disclosure further provides polynucleotides encoding the antibodies described herein, e.g., polynucleotides encoding heavy or light chain variable regions or segments comprising the complementarity determining regions as described herein.
[0127] The polynucleotides of the present disclosure can encode the variable region sequence of an anti-OX40 or anti-PD1 antibody. They can also encode both a variable region and a constant region of an anti-OX40 or anti-PD1 antibody. Some of the polynucleotide sequences encode a polypeptide that comprises variable regions of both the heavy chain and the light chain of one of the exemplified antibodies. Some other polynucleotides encode two polypeptide segments that are substantially identical to the variable regions of the heavy chain and the light chain of one of the antibodies.
[0128] Also provided in the present disclosure are expression vectors and host cells for producing the antibodies. The choice of expression vector depends on the intended host cells in which the vector is to be expressed. The expression vectors may contain a promoter and other regulatory sequences (e.g., enhancers) that are operably linked to the polynucleotides encoding an antibody chain or antigen-binding fragment. In some aspects, an inducible promoter is employed to prevent expression of inserted sequences except under the control of inducing conditions. Inducible promoters include, e.g., arabinose, lacZ, metallothionein promoter or a heat shock promoter. Cultures of transformed organisms can be expanded under non-inducing conditions without biasing the population for coding sequences whose expression products are better tolerated by the host cells. In addition to promoters, other regulatory elements can also be included for efficient expression of an antibody or antigen-binding fragment thereof. These elements may include an ATG initiation codon and adjacent ribosome binding site or other sequences. In addition, the efficiency of expression can be enhanced by the inclusion of enhancers appropriate to the cell system in use (see, e.g., Scharf et al., Results Probl. Cell Differ. 20: 125, 1994; and Bittner et al., Meth. Enzymol., 153: 516, 1987) . For example, the SV40 enhancer or CMV enhancer can be used to increase expression in mammalian host cells.
[0129] The host cells for harboring and expressing the antibody vectors can be either prokaryotic or eukaryotic. E. coli is one prokaryotic host useful for cloning and expressing the polynucleotides of the present disclosure. Other microbial hosts suitable for use include bacilli, such as Bacillus subtilis, and other enterobacteriaceae, such as Salmonella, Serratia, and various Pseudomonas species. In these prokaryotic hosts, one can also make expression vectors, which typically contain expression control sequences compatible with the host cell (e.g., an origin of replication) . In addition, any number of a variety of well-known promoters may be present, such as the lactose promoter system, a tryptophan (trp) promoter system, a beta-lactamase promoter system, or a promoter system from phage lambda. The promoters typically control expression, optionally with an operator sequence, and have ribosome binding site sequences and the like, for initiating and completing transcription and translation. Other microbes, such as yeast, can also be employed to express antibodies. Insect cells in combination with baculovirus vectors can also be used.
[0130] In other aspects, mammalian host cells are used to express and produce the antibodies of the present disclosure. Examples include a hybridoma cell line expressing endogenous immunoglobulin genes or a mammalian cell line harboring an exogenous expression vector. These include any normal mortal or normal or abnormal immortal animal or human cells. For example, several suitable host cell lines capable of secreting intact immunoglobulins have been developed, including the CHO cell lines, various COS cell lines, HEK 293 cells, myeloma cell lines, transformed B-cells and hybridomas. The use of mammalian tissue cell culture to express polypeptides is discussed generally in, e.g., Winnacker, From Genes to Clones, VCH Publishers, NY, N.Y., 1987. Expression vectors for mammalian host cells can include expression control sequences, such as an origin of replication, a promoter, and an enhancer (see, e.g., Queen et al., Immunol. Rev. 89: 49-68, 1986) , and necessary processing information sites, such as ribosome binding sites, RNA splice sites, polyadenylation sites, and transcriptional terminator sequences. These expression vectors usually contain promoters derived from mammalian genes or from mammalian viruses. Suitable promoters can be constitutive, cell type-specific, stage-specific, and / or modulatable or regulatable. Useful promoters include, but are not limited to, the metallothionein promoter, the constitutive adenovirus major late promoter, the dexamethasone-inducible MMTV promoter, the SV40 promoter, the MRP polIII promoter, the constitutive MPSV promoter, the tetracycline-inducible CMV promoter (such as the human immediate-early CMV promoter) , the constitutive CMV promoter, and promoter-enhancer combinations known in the art.
[0131] Methods of Treatment
[0132] The antibodies or antigen-binding fragments of the present disclosure are useful in a variety of applications including, but not limited to, methods for the treatment of an OX40- associated disorder or disease. In one aspect, the OX40-associated disorder or disease is a cancer.
[0133] In one aspect, the present disclosure provides a method of treating cancer. In certain aspects, the method comprises administering to a patient in need thereof an effective amount of an anti-OX40 antibody or antigen-binding fragment in combination with an anti-PD1 antibody or antigen binding fragment thereof.
[0134] Anti-PD1 antibodies can include, without limitation, antibodies disclosed in US Patent No. 8,735,553. Anti-PD1 antibodies can include pembrolizumab (formerly MK-3475) , as disclosed by Merck. Pembrolizumab is a humanized lgG4-K immunoglobulin with a molecular weight of about 149 kDa, which targets the PD1 receptor and inhibits binding of the PD1 receptor ligands PD-L1 and PD-L2. Pembrolizumab has been approved for the indications of metastatic melanoma and metastatic non-small cell lung cancer (NSCLC) and is under clinical investigation for the treatment of head and neck squamous cell carcinoma (HNSCC) and refractory Hodgkin's lymphoma (cHL) . Nivolumab (as disclosed by Bristol-Meyers Squibb) is a fully human lgG4-K monoclonal antibody. Nivolumab (clone 5C4) is disclosed in US Patent No. US 8,008,449 and WO 2006 / 121 168. Nivolumab is approved for the treatment of melanoma, lung cancer, kidney cancer, and Hodgkin's lymphoma.
[0135] The cancer can include, without limitation, breast cancer, colon cancer, anal cancer, peritoneal cancer, bladder cancer, pancreatic cancer, head and neck cancer, gastric cancer, gastroesophageal junction cancer, kidney cancer, liver cancer, small cell lung cancer, non-small cell lung cancer, ovarian cancer, cervical cancer, endometrial cancer, uterine cancer, skin cancer, mesothelioma, lymphoma, leukemia, myeloma, or sarcoma.
[0136] Presently disclosed antibodies or antigen-binding fragments can be administered by any suitable means, including parenteral, intrapulmonary, intranasal, and, if desired for local treatment, intralesional administration. Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration. Dosing can be by any suitable route, e.g., by injections, such as intravenous or subcutaneous injections, depending in part on whether the administration is brief or chronic. Various dosing schedules including but not limited to single or multiple administrations over various time-points, bolus administration, and pulse infusion are contemplated herein.
[0137] Presently disclosed antibodies or antigen-binding fragments are formulated, dosed, and administered in a fashion consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners. The antibody need not be, but is optionally formulated with, one or more agents currently used to prevent or treat the disorder in question. The effective amount of such other agents depends on the amount of antibody present in the formulation, the type of disorder or treatment, and other factors discussed above. These are generally used in the same dosages and with administration routes as described herein, or from about 1 to 99%of the dosages described herein, or in any dosage and by any route that is empirically / clinically determined to be appropriate.
[0138] For the prevention or treatment of disease, the appropriate dosage of a presently disclosed antibody or antigen-binding fragment will depend on the type of disease to be treated, the type of antibody, the severity and course of the disease, whether the antibody is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the antibody, and the discretion of the attending physician. The antibody is suitably administered to the patient at one time or over a series of treatments. Depending on the type and severity of the disease, about 1 μg / kg to 100 mg / kg of antibody can be an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion. One typical daily dosage might range from about 1 μg / kg to 100 mg / kg or more, depending on the factors mentioned above. For repeated administrations over several days or longer, depending on the condition, the treatment would generally be sustained until a desired suppression of disease symptoms occurs. Such doses can be administered intermittently, e.g., every week or every three weeks (e.g., such that the patient receives from about two to about twenty, or e.g., about six doses of the antibody) . An initial higher loading dose, followed by one or more lower doses can be administered. However, other dosage regimens can be useful. The progress of this therapy is easily monitored by conventional techniques and assays.
[0139] The anti-OX40 antibodies disclosed herein may be administered at from 20 mg to 3600 mg, from 20 mg to 2400 mg, from 20 mg to 1200 mg, from 20 mg to 900 mg, from 20 mg to 600 mg, from 20 mg to 300 mg, from 20 mg to 150 mg, from 20 mg to 60 mg, from 60 mg to 3600 mg, from 150 mg to 3600 mg, from 300 mg to 3600 mg, from 600 mg to 3600 mg, from 900 mg to 3600 mg, from 1220 mg to 3600 mg, or from 2400 mg to 3600 mg. The anti-OX40 antibodies disclosed herein may be administered at 20 mg, 60 mg, 150 mg, 300 mg, 600 mg, 900 mg, 1200 mg, 2400 mg, or 3600 mg. The anti-OX40 antibodies can be administered twice per day, daily, once per week, twice per week, three times per week, four times per week, five times per week, once every two weeks, once every three weeks, once every month, once every two months, once every three months, once every four months, once every five months, or once every six months.
[0140] In some embodiments, the dosing regimen comprises administering, in combination with the anti-OX40 antibodies, an anti-PD1 antibody. The anti-PD1 antibody may be BGB-A317. The anti-PD1 antibody may be administered at from 100 mg to 600 mg, from 100 mg to 500 mg, from 100 mg to 400 mg, from 100 mg to 300 mg, from 100 mg to 200 mg, from 200 mg to 600 mg, from 300 mg to 600 mg, from 400 mg to 600 mg, or from 500 mg to 600 mg. The anti-PD1 antibody may be administered at 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, or 600 mg. In some embodiments, the dosing regimen comprises administering the anti-PD1 antibody, such as BGB-A317, at 100 mg once every three weeks. In some embodiments, the dosing regimen comprises administering the anti-PD1 antibody at 200 mg once every three weeks. In some embodiments, the dosing regimen comprises administering the anti-PD1 antibody at 300 mg once every three weeks. In some embodiments, the dosing regimen comprises administering the anti-PD1 antibody at 400 mg once every three weeks. In some embodiments, the dosing regimen comprises administering the anti-PD1 antibody at 500 mg once every three weeks. In some embodiments, the dosing regimen comprises administering the anti-PD1 antibody at 600 mg once every three weeks.
[0141] In some aspects, a patient may experience a sustained anti-cancer response after cessation of treatment at any treatment dose and frequency of administration.
[0142] Other Combination Therapies
[0143] In one aspect, anti-OX40 antibodies of the present disclosure can be used in combination with therapeutic agents other than, or in addition to, anti-PD1 antibodies.
[0144] Other therapeutic agents that can be used with the anti-OX40 antibodies of the present disclosure include, but are not limited to, a chemotherapeutic agent (e.g., paclitaxel or a paclitaxel agent (e.g., ) , docetaxel, carboplatin, topotecan, cisplatin, irinotecan, doxorubicin, lenalidomide, 5-azacytidine, ifosfamide, oxaliplatin, pemetrexed disodium, cyclophosphamide, etoposide, decitabine, fludarabine, vincristine, bendamustine, chlorambucil, busulfan, gemcitabine, melphalan, pentostatin, mitoxantrone, pemetrexed disodium) , tyrosine kinase inhibitor (e.g., EGFR inhibitor (e.g., erlotinib) ) , multikinase inhibitor (e.g., MGCD265, RGB-286638) , CD-20 targeting agent (e.g., rituximab, ofatumumab, RO5072759, LFB-R603) , CD52 targeting agent (e.g., alemtuzumab) , prednisolone, darbepoetin alfa, lenalidomide, Bcl-2 inhibitor (e.g., oblimersen sodium) , aurora kinase inhibitor (e.g., MLN8237, TAK-901) , proteasome inhibitor (e.g., bortezomib) , CD-19 targeting agent (e.g., MEDI-551, MOR208) , MEK inhibitor (e.g., ABT-348) , JAK-2 inhibitor (e.g., INCB018424) , mTOR inhibitor (e.g., temsirolimus, everolimus) , BCR / ABL inhibitor (e.g., imatinib) , ET-A receptor antagonist (e.g., ZD4054) , TRAIL receptor 2 (TR-2) agonist (e.g., CS-1008) , HGF / SF inhibitor (e.g., AMG 102) , EGEN-001, or Polo-like kinase 1 inhibitor (e.g., BI 672) .
[0145] Pharmaceutical Compositions and Formulations
[0146] Also provided are compositions, including pharmaceutical formulations, comprising an anti-OX40 antibody or antigen-binding fragment, or polynucleotides comprising sequences encoding an anti-OX40 antibody or antigen-binding fragment. In certain embodiments, compositions comprise one or more antibodies or antigen-binding fragments that bind to OX40, or one or more polynucleotides comprising sequences encoding one or more antibodies or antigen-binding fragments that bind to OX40. These compositions can further comprise suitable carriers, such as pharmaceutically acceptable excipients including buffers, which are well known in the art.
[0147] Also provided are compositions, including pharmaceutical formulations, comprising an anti-PD1 antibody or antigen-binding fragment, or polynucleotides comprising sequences encoding an anti-PD1 antibody or antigen-binding fragment. In certain embodiments, compositions comprise one or more antibodies or antigen-binding fragments that bind to PD1, or one or more polynucleotides comprising sequences encoding one or more antibodies or antigen-binding fragments that bind to PD1. These compositions can further comprise suitable carriers, such as pharmaceutically acceptable excipients including buffers, which are well known in the art.
[0148] Pharmaceutical formulations of an anti-OX40 antibody or antigen-binding fragment, and / or of an anti-PD1 antibody or antigen-binding fragment, as described herein are prepared by mixing such antibody or antigen-binding fragment having the desired degree of purity with one or more optional pharmaceutically acceptable carriers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980) ) , in the form of lyophilized formulations or aqueous solutions. Pharmaceutically acceptable carriers are generally nontoxic to recipients at the dosages and concentrations employed, and include, but are not limited to, buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol) ; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g., Zn-protein complexes) ; and / or non-ionic surfactants such as polyethylene glycol (PEG) .
[0149] Exemplary lyophilized antibody formulations are described in US Patent No. 6,267,958. Aqueous antibody formulations include those described in US Patent No. 6,171,586 and WO2006 / 044908, the latter formulations including a histidine-acetate buffer.
[0150] Sustained-release preparations can be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, or microcapsules.
[0151] The formulations to be used for in vivo administration are generally sterile. Sterility can be readily accomplished, e.g., by filtration through sterile filtration membranes.
[0152] It is to be understood that, while the anti-OX40 and anti-PD1 antibodies and antigen binding fragments thereof have been described in conjunction with a detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the disclosure, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the claims below.
[0153] It is to be understood that one, some, any, or all of the features of the various embodiments disclosed herein may be combined to form further embodiments of the present disclosure. These and other aspects of the present disclosure will be apparent to those skilled in the art.
[0154] EXAMPLES
[0155] Example 1: BGB-A445 anti-tumor activity in a mouse tumor model
[0156] The efficacy of anti-OX40 antibody BGB-A445 was investigated in a mouse tumor model. Murine MC38 colon tumor cells were subcutaneously implanted in C57 mice transgenic for human OX40 (Biocytogen, Beijing China) . After implantation of tumor cells, tumor volumes were measured twice weekly and calculated in mm3 using the formula: V = 0.5 (a x b2) where a and b were the long and short dimensions of the tumor, respectively. When tumors reached a mean volume of approximately 190 mm3 in size, mice were randomly allocated into 7 groups, and injected intraperitoneally with either BGB-A445 or Reference OX40 antibody 1A7. gr1 once a week for three weeks. Human IgG was administered as isotype control. Partial regression (PR) was defined as tumor volume smaller than 50%of the starting tumor volume on the first day of dosing in three consecutive measurements. Tumor growth inhibition (TGI) was calculated using the following formula:
[0157] treated t = treated tumor volume at time t
[0158] treated t0 = treated tumor volume at time 0
[0159] placebo t = placebo tumor volume at time t
[0160] placebo t0 = placebo tumor volume at time 0
[0161] Results are presented in Figures 1A-1C. BGB-A445 showed dose-dependent anti-tumor efficacy as an intraperitoneal injection with doses of 0.4 mg / kg, 2 mg / kg, and 10 mg / kg (Figure 1A) . The data are presented as the mean body weight ± SEM for 10 animals in each group. In contrast, no partial regression by Reference OX40 antibody 1A7. gr1 was observed (Figure 1B) . The in vivo data indicate that ligand-non-blocking antibody BGB-A445 is better suited for anti-tumor therapy than the OX40-OX40L blocking Reference OX40 antibody 1A7. gr1 (Figures 1A and 1B) . Figure 1C shows a comparison of tumor growth inhibition (TGI) between the two antibodies, taken out to day 16 with BGB-A445 showing a prolonged inhibition of tumor growth as opposed to the decline in TGI shown by the Reference OX40 antibody.
[0162] Example 2: BGB-A445 antibodies in combination with anti-PD1 antibodies in a murine colon tumor (MC38) humanized OX40 knock-in mouse model
[0163] Female humanized OX40 knock-in mice (B-hOX40 or hOX40) were subcutaneously implanted with 1 × 106 murine colon carcinoma cells (MC38) in 100 μL PBS into the right flank of the mouse. After inoculation, animals were randomized into 4 groups with 9 animals in each group. Mice were treated with vehicle (placebo buffer) , BGB-A445 as a single agent, an in-house generated murine anti-PD1 antibody (muPD1) as a single agent, and BGB-A445 in combination with muPD1. The BGB-A445 and muPD1 antibodies were administered at 3 mg / kg once per week (QW) by intraperitoneal (i. p. ) injection. Tumor volume was determined twice weekly in two dimensions using a caliper and was expressed in mm3 using the formula: V = 0.5 (a× b2) where a and b were the long and short dimensions of the tumor, respectively. Data is presented as mean tumor volume ± standard error of the mean (SEM) .
[0164] The anti-tumor activity of BGB-A445 antibody and muPD1 in MC38 syngeneic model in hOX40 mice is shown in Table 3 and Figure 2. The results demonstrate that OX40 antibodies, for example BGB-A445, administered in combination with anti-PD1 antibodies are efficacious in a mouse colon tumor model, and superior to each agent administered as monotherapy. There was no significant impact on animal body weight in any treatment group throughout the study.
[0165] Table 3 a All doses administered once a week. b not applicable
[0166] Example 3: BGB-A445 effects on T cell activation and dendritic cell (DC) maturation
[0167] Human CD4+ T cells and CD14+ monocytes were isolated from peripheral blood mononuclear cells (PBMCs) of healthy donors using magnetic beads according to the manufacturer’s instructions (Miltenyi, Cat.: 130-096-533 and Cat.: 130-050-201) . Purified CD4+ T cells were cryopreserved in liquid nitrogen before the assay. CD14+ monocytes were then cultured with GM-CSF (Sino Biological, Cat.: 10015-H07H, 100 ng / mL) and IL-4 (Sino Biological, Cat.: GMP-11846-HNAE, 100 ng / mL) for 5 days. Loosely adherent cells (monocyte-derived immature DCs) were collected by gentle pipetting. In the coculture, purified CD4+ T cells (freshly thawed, 2x104 / well) were mixed with DCs (104 / well) in the presence of SEB (in-house produced, 0.1 μg / mL) and anti-OX40 antibodies in 96-well plates for 3 days. In some cases, an anti-OX40L blocking polyclonal antibody (R&D Systems, Cat.: AF1054) was added to the coculture to determine the effects of endogenous OX40-OX40L interaction on CD4+ T cells and DCs. IL-2 production in the supernatant was determined by ELISA (Invitrogen, Cat.: 887025) . The expression of CD83 and CD86 on DCs was examined with APC / Cyanine7-conjugated anti-CD83 (BioLegend, Cat.: 305330) and APC-conjugated anti-CD86 (BioLegend, Cat.: 374208) , respectively. The samples were subjected to flow cytometry analysis with a NovoCyte 3005 and NovoExpress software (version 1.4.1) .
[0168] Results are presented in Figures 3A-3D. For Figures 3A and 3B, the data shown are representative of at least 3 independent experiments from multiple donors. The data are presented as the mean ± SD. (*p<0.05) . IL-2 secretion by T cells (Figures 3A and 3B) and the expression of costimulatory molecules CD83 (Figure 3C) and CD86 (Figure 3D) on DCs were determined by ELISA and flow cytometry, respectively. The indicated OX40 mAbs (10 μg / mL) were added to the coculture system alone or in combination with OX40L-blocking antibodies (10 μg / mL) .
[0169] The results show BGB-A445 induces dose-dependent T cell activation and DC maturation.
[0170] Example 4: A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of the Anti OX40 Agonist Monoclonal Antibody BGB-A445 in Combination with the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumors
[0171] The disclosed antibodies were studied in an open-label, multicenter, nonrandomized, Phase 1a dose-escalation and Phase 1b dose expansion study investigating safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of the OX40 agonist monoclonal antibody BGB-A445 alone and in combination with the anti-PD-1 monoclonal antibody tislelizumab in patients with advanced solid tumors. The study design is shown in Figure 4. Each therapy was administered once every three weeks.
[0172] Phase 1a (Dose Escalation)
[0173] Sequential cohorts of 8 increasing dose levels of BGB-A445 monotherapy (Part A) and 6 increasing dose levels of BGB-A445 in combination with 200 mg of tislelizumab (Part B) were evaluated to determine the recommended phase II dose (RP2D) , safety, pharmacokinetics (PK) , and other key endpoints. Enrollment was limited to patients with advanced solid tumors for which there is clinical evidence of response to T cell-based immune oncology agents (e.g., anti-PD-1) or other scientific evidence in support of an immunologically sensitive tumor type.
[0174] Dose escalation of BGB-A445 alone (Part A) or in combination with 200 mg of tislelizumab (Part B) was conducted across approximately 10 centers in, for example, Australia, New Zealand, the United States, and China.
[0175] Phase 1b (Dose Expansion)
[0176] After completion of Phase 1a (Dose Escalation) , enrollment commenced in the Phase 1b (Dose Expansion) to determine the RP2D based on evaluation of BGB-A445 monotherapy at the selected 3 to 4 dose levels (Part A) . Additional safety, PK, and other key endpoints were evaluated.
[0177] Patients with NSCLC or HNSCC who have previously received standard systemic therapy for advanced or metastatic disease or whose disease has progressed within 6 months following completion of systemic therapy for local disease were enrolled in Part A.
[0178] Patients with recurrent or metastatic NPC were enrolled in Part B.
[0179] For each cohort in the expansion phase (Parts A and B) , an interim analysis was conducted based on approximately 20 patients who have had at least one on-study tumor assessment. Up to 40 patients can be enrolled per cohort, with an early stopping rule set-up.
[0180] All patients received study drug (s) until 1) they are no longer considered to be achieving clinical benefit, 2) they have unacceptable toxicity, or 3) they withdraw informed consent.
[0181] Safety and tolerability were determined by the spontaneous reporting of adverse events (AEs) and by laboratory values (hematology, clinical chemistry, coagulation, and urinalysis) . Vital signs, physical examinations, and ECG findings were also be used in determining the safety profile. The severity of AEs were graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE v5.0) . The incidence of Dose-Limiting Toxicity (DLT) events and TEAEs were reported as the number (percentage) of patients with TEAEs by Medical Dictionary for Regulatory Activities (MedDRA) system organ class and preferred term. Descriptive summary statistics (e.g., n, mean, standard deviation, median, minimum, and maximum for continuous variables; n [%] for categorical variables) and changes from baseline were determined for laboratory parameters and vital signs.
[0182] Primary Outcome Measures
[0183] Phase 1a: Number of participants experiencing AEs up to 90 days after the last dose of study drug regardless of whether the participant starts a subsequent anticancer therapy.
[0184] Phase 1a: Number of participants experiencing serious adverse events (SAEs) up to 90 days after the last dose of study drug regardless of whether the participant starts a subsequent anticancer therapy.
[0185] Phase 1a: Number of participants experiencing AEs meeting protocol defined DLT criteria up to 90 days after the last dose of study drug regardless of whether the participant starts a subsequent anticancer therapy.
[0186] Phase 1a: Maximum tolerated dose (MTD) of BGB-A445 evaluated up to 30 days after the last dose of study drug or before the initiation of a new anticancer treatment, whichever occurs first. The MTD is defined as the highest dose evaluated for which the estimated toxicity rate is closest to the target toxicity rate of 30%.
[0187] Phase 1b: RP2D of BGB-A445 when administered alone, evaluated up to 30 days after the last dose of study drug (s) or before the initiation of a new anticancer treatment, whichever occurs first.
[0188] Secondary Outcome Measures
[0189] Phase 1a: Overall response rate (ORR) as assessed by the investigator, evaluated up to 30 days after the last dose of study drug (s) or before the initiation of a new anticancer treatment, whichever occurs first. ORR is defined as the proportion of participants who had confirmed complete response (CR) or partial response (PR) as assessed by the investigator using RECIST v1.1.
[0190] Phase 1a: Duration of response (DOR) as assessed by the investigator, evaluated up to 30 days after the last dose of study drug (s) or before the initiation of a new anticancer treatment, whichever occurs first.
[0191] Phase 1a: Disease-control rate (DCR) as assessed by the investigator, evaluated up to 30 days after the last dose of study drug (s) or before the initiation of a new anticancer treatment, whichever occurs first.
[0192] Phase 1a: Serum concentration of BGB-A445, evaluated from 60 minutes predose up to 72 hours postdose.
[0193] Phase 1a: Serum concentration of tislelizumab, evaluated from 60 minutes predose up to 72 hours postdose.
[0194] Phase 1a: Maximum observed plasma concentration (Cmax) of BGB-A445, evaluated from 60 minutes predose up to 72 hours postdose.
[0195] Phase 1a: Cmax of tislelizumab, evaluated from 60 minutes predose up to 72 hours postdose.
[0196] Phase 1a: Minimum observed plasma concentration (Cmin) of BGB-A445, evaluated from 60 minutes predose up to 72 hours postdose.
[0197] Phase 1a: Cmin of tislelizumab, evaluated from 60 minutes predose up to 72 hours postdose.
[0198] Phase 1a: Time to maximum plasma concentration (Tmax) of BGB-A445, evaluated from 60 minutes predose up to 72 hours postdose.
[0199] Phase 1a: Tmax of tislelizumab, evaluated from 60 minutes predose up to 72 hours postdose.
[0200] Phase 1a: Area under the concentration-time curve of 0-21 days (AUC0-21d) of BGB-A445, evaluated from 60 minutes predose up to 21 days postdose.
[0201] Phase 1a: Immunogenic responses to BGB-A445 as assessed through the detection of antidrug antibodies, evaluated up to 30 days after the last dose of study drug (s) or before the initiation of a new anticancer treatment, whichever occurs first.
[0202] Phase 1a: Immunogenic responses to tislelizumab as assessed through the detection of antidrug antibodies, evaluated up to 30 days after the last dose of study drug (s) or before the initiation of a new anticancer treatment, whichever occurs first.
[0203] Phase 1b: Progression-free survival (PFS) as assessed by the investigator, evaluated up to 30 days after the last dose of study drug (s) or before the initiation of a new anticancer treatment, whichever occurs first.
[0204] The following outcome measures are determined from investigator-derived tumor assessments as per RECIST 1.1.
[0205] Phase 1b: ORR as assessed by the investigator, evaluated up to 30 days after the last dose of study drug (s) or before the initiation of a new anticancer treatment, whichever occurs first.
[0206] Phase 1b: DOR as assessed by the investigator, evaluated up to 30 days after the last dose of study drug (s) or before the initiation of a new anticancer treatment, whichever occurs first.
[0207] Phase 1b: DCR as assessed by the investigator, evaluated up to 30 days after the last dose of study drug (s) or before the initiation of a new anticancer treatment, whichever occurs first.
[0208] Phase 1b: Number of participants experiencing AEs up to 90 days after the last dose of study drug regardless of whether the participant starts a subsequent anticancer therapy.
[0209] Phase 1b: Number of participants experiencing SAEs up to 90 days after the last dose of study drug regardless of whether the participant starts a subsequent anticancer therapy.
[0210] Phase 1b: Serum concentration of BGB-A445, evaluated from 60 minutes predose up to 72 hours postdose.
[0211] Phase 1b: Cmax of BGB-A445, evaluated from 60 minutes predose up to 72 hours postdose.
[0212] Phase 1b: Cmin of BGB-A445, evaluated from 60 minutes predose up to 72 hours postdose.
[0213] Phase 1b: Tmax of BGB-A445, evaluated from 60 minutes predose up to 72 hours postdose.
[0214] Phase 1b: AUC0-21d of BGB-A445, evaluated from 60 minutes predose up to 21 days postdose.
[0215] Phase 1b: Phase 1a: Immunogenic responses to BGB-A445 as assessed through the detection of antidrug antibodies, evaluated up to 30 days after the last dose of study drug (s) or before the initiation of a new anticancer treatment, whichever occurs first.
[0216] Key Inclusion Criteria
[0217] Phase 1a (Dose Escalation) : Patients with histologically or cytologically confirmed advanced, metastatic, unresectable solid tumors who had previously received standard systemic therapy or for whom treatment was not available, not tolerated, or refused.
[0218] Enrollment was limited to participants with advanced solid tumors for which there is clinical evidence of response to T cell-based immuno-oncology agents (e.g., anti-PD-1) or other scientific evidence in support of an immunologically sensitive tumor type.
[0219] Participant had not received prior therapy targeting OX40 or any other T cell agonist therapy (prior checkpoint inhibitor therapy was allowed) .
[0220] Phase 1b (Dose Expansion) : Patients described in the following cohorts for whom standard systemic treatment was not available, not tolerated, or determined not appropriate based on investigator’s judgement.
[0221] Cohort 1 (NSCLC) : Patients with histologically or cytologically confirmed stage IIIB, IIIC, or IV disease whose tumor was not amenable to local therapy with curative intent (i.e., surgery or radiotherapy with or without chemotherapy) , who have received ≥ 1, but no more than 3, lines of prior systemic therapy for advanced or metastatic disease. Patients who progressed within 6 months following completion of systemic therapy for local disease should have received a platinum-based agent. Patients who were eligible to receive targeted therapy (if actionable oncogenic driver mutations with locally approved therapy were identified [e.g., EGFR, ALK, or other] ) must have received appropriate targeted therapy.
[0222] Cohort 2 (HNSCC) : Patients with histologically or cytologically confirmed recurrent or metastatic head and neck squamous cell cancer whose tumor was not amenable to local therapy with curative intent (i.e., surgery or radiotherapy with or without chemotherapy) , and who have received ≥ 1, but no more than 3, lines of prior systemic therapy for recurrent or metastatic disease or progressed within 6 months following completion of systemic therapy for local disease.
[0223] Patient had at least 1 measurable lesion as defined per RECIST 1.1. The target lesion (s) selected had not been previously treated with local therapy or the target lesion (s) selected that are within the field of prior local therapy had subsequently progressed as defined by RECIST 1.1
[0224] Key Exclusion Criteria
[0225] Active leptomeningeal disease or uncontrolled brain metastasis. Participants with equivocal findings or with confirmed brain metastases were eligible for enrollment provided they were asymptomatic and radiologically stable without the need for corticosteroid treatment for at least 4 weeks prior to the first dose of study drug (s) .
[0226] Active autoimmune diseases or history of autoimmune diseases that may relapse or history of life-threatening toxicity related to prior immune therapy, with the following exceptions:
[0227] Controlled type 1 diabetes
[0228] Hypothyroidism (provided it was managed with hormone-replacement therapy only) Controlled celiac disease
[0229] Skin diseases not requiring systemic treatment (e.g., vitiligo, psoriasis, or alopecia)
[0230] Any other disease that is not expected to recur in the absence of external triggering factors (required consultation with the medical monitor prior to enrollment) .
[0231] Any active malignancy ≤ 2 years before the first dose of study drug (s) except for the specific cancer under investigation in the instant study and any locally recurring cancer that had been treated with curative intent (e.g., resected basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast) .
[0232] Example 5: Results of patient enrollment
[0233] As of August 31, 2022, 59 patients were enrolled in Part A (BGB-A445 from 20 mg to 2400 mg) and 32 patients were enrolled in Part B (BGB-A445 from 150 mg to 2400 mg) .
[0234] As of April 30, 2023, 63 patients were enrolled in Part A and 49 patients were enrolled in Part B. The patient demographics and baseline characteristics as of April 30, 2023 are shown in Figures 5A and 5B, and as of March 1, 2024, are shown in Figures 5C-5F.
[0235] Example 6: Results of safety analyses at increasing dosages of BGB-A445
[0236] Summaries of adverse events as of August 31, 2022, are shown in Figures 6A and 6B, as of April 30, 2023, in Figures 6C and 6D, and as of March 1, 2024, in Figures 6E and 6F. As of August 31, 2022, there were Grade ≥ 3 treatment emergent adverse events (TEAE) reported in 24 patients (40.7%) in Part A, which was directed to BGB-A445 as monotherapy. When BGB-A445 was combined with a fixed dose of BGB-A317 (200 mg / QW3) , there were 17 patients with Grade ≥ 3 TEAEs (53.1%) , the most common of which were gastrointestinal disorders such as diarrhea and abdominal pain. In Part A, no Grade ≥ 3 TEAE occurred in 5%of the total group. In Part B, there were 4 Grade ≥ 3 TEAEs reported in ≥ 5%of the total group (diarrhea, 3 patients [9.4%] ; abdominal pain, pleural effusion, and pyrexia in 2 patients [6.3%] each) . Grade ≥ 3 immune mediated AEs (imAEs) did not occur in any patient in Part A and in 1 patient (3.1%maculopapular rash and diarrhea) in Part B. There were no dose-limiting toxicities in either Part A or Part B. Treatment related adverse events leading to discontinuation of BGB-A445 occurred in 1 patient (1.7%) in Part A at the 2400 mg dose and no patients discontinued treatment in Part B. Lastly, there were no deaths due to adverse events in either Part A or Part B.
[0237] Figures 6C and 6D include data up to April 30, 2023, and Figures 6E and 6F include date up to March 1, 2024, all of which include doses of up to 3600 mg BGB-A445. The figures show that BGB-A445 at up to 3600 mg as monotherapy and combination therapy demonstrated a favorable safety and tolerability profile, promising antitumor activity, and no dose limiting toxicities.
[0238] Example 7: Results of efficacy at increasing dosages of BGB-A445
[0239] Figures 7A-7D show swimlane plots of the effects of different doses of BGB-A445 on different types of cancers. Figures 8A-8D show waterfall plots of best change in tumor size (as a percent) from baseline as determined by investigator assessment. Within both analyses, the dosing ranged from 20 mg BGB-A445 to 3600 mg BGB-A445.
[0240] The abbreviations for all of Figures 7A-8D are as follows: A: anal cancer, B2: bladder cancer, C1: cervical cancer, CRC: colorectal cancer, E1: endometrial cancer; GC: gastric cancer or GEJ cancer, HNC: head and neck cancer, K: kidney cancer, L1N: non-small cell lung cancer -non squamous, L1S: non-small cell lung cancer -squamous, L2: small cell lung cancer, M: melanoma, P1: pancreatic cancer, P2: peritoneal cancer, UC: uterine cancer, and O: all others.
[0241] The summary of results for Part A, as of August 31, 2022, is shown in Figure 7A and Figure 8A. As of that date, of the 50 patients treated with BGB-A445 as monotherapy under Part A, 2 patients (4.0%) achieved partial response in uterine carcinosarcoma at a dosage of 1200 mg. For patients with metastatic lung adenocarcinoma, 18 had stable disease (36.0%) , and 26 had progressive disease (52.0%) at a dosage of 2400 mg.
[0242] The summary of results for Part A, as of March 1, 2024, is shown in Figure 7C and Figure 8C. As of that date, of 61 patients treated with BGB-A445 as monotherapy under Part A, 2 patients (3.3%) achieved partial response (unconfirmed) in uterine carcinosarcoma at a dosage of 1200 mg. For patients with metastatic lung adenocarcinoma, 20 (32.8%) had stable disease at a dosage of 2400 mg. For patients with metastatic lung adenocarcinoma, 20 (32.8%) had stable disease, 37 patients (60.7%) had progressive disease, and 4 patients (6.6%) were not evaluable.
[0243] The summary of results for Part B (BGB-A445 in combination with BGB-A317) , as of August 31, 2022, is shown in Figure 7B and Figure 8B. As of that date, of the 30 patients evaluated, 7 patients had a partial response (23.3%) in colorectal cancer (BGB-A445 at 150 mg) , anal cancer (BGB-A445 at 150 mg) , cervical cancer (BGB-A445 at 300 mg) , bladder cancer (BGB-A445 at 600 mg) , urothelial cancer (BGB-A445 at 600 mg) , NSCLC non-squamous (BGB-A445 at 1200 mg) , and colorectal cancer (BGB-A445 at 1200 mg) . BGB-A317 was kept at a dose of 200 mg. Overall, 13 patients (43%) had stable disease, 8 patients (26.7%) had progressive disease, and 2 patients were not evaluable.
[0244] The summary of results for Part B (BGB-A445 in combination with BGB-A317) , as of March 1, 2024, is shown in Figure 7D and Figure 8D. As of that date, of the 49 patients evaluated, 10 patients had a partial response (21.3%) in colorectal cancer (BGB-A445 at 150 mg) , anal cancer (BGB-A445 at 150 mg) , cervical cancer (BGB-A445 at 300 mg) , bladder cancer (BGB-A445 at 600 mg) , urothelial cancer (BGB-A445 at 600 mg) , NSCLC non-squamous (BGB-A445 at 1200 mg) , SCLC (BGB -A445 at 1200 mg) , colorectal cancer (BGB-A445 at 1200 mg) , colorectal carcinoma (BGB-A445 2400mg ) and NSCLC adenocarcinoma (BGB-A445 3600 mg) . BGB-A317 was kept at a dose of 200 mg. Overall, 15 patients (31.9%) had stable disease, 19 patients (40.4%) had progressive disease, and 3 patients (6.4%) were not evaluable.
[0245] Example 8: BGB-A445 Pharmacokinetics and Pharmacodynamics
[0246] Both PK and PD of BGB-A445 were evaluated . The exposure of BGB-A445 was similar in Part A (monotherapy) as in Part B (BGB-A445 combined with BGB-A317) . The pharmacokinetics of BGB-A445, including maximum concentration and area under the curve from day 0 to day 21, were linear and dose proportional in all tested dose ranges. The mean serum concentration of BGB-A445 and BGB-A445 in combination with BGB-A317 is shown in Figures 9A-9C. Unlike other anti-OX40 antibodies, BGB-A445 does not show a “hook” effect.
[0247] Example 9: OX40 Receptor Occupancy on Peripheral CD4+ T cells in BGB-A445 Monotherapy and Combination Therapy Across Doses
[0248] Peripheral whole blood samples were collected from each patient at multiple timepoints for pharmacodynamic biomarker analysis. The blood samples were incubated with a saturating dose of BGB-A445 to measure total OX40 expression or without BGB-A445 incubation to measure OX40 bound by BGB-A445. Then the samples were washed and incubated with fluorescent-labeled anti-human-IgG1 and surface markers. After washing steps, samples were analyzed by flow cytometry.
[0249] As of a data update from 05 January 2024, peripheral OX40 receptor occupancy data were available for a total of 63 patients who were treated with BGB-A445 as monotherapy (20 mg to 3600 mg every 3 weeks) and 49 patients on combination therapy (150 mg to 3600 mg every 3 weeks) with tislelizumab (200 mg) . As shown in Figure 10, almost complete and sustained OX40 receptor occupancy (> 90%) was observed on CD4+ T cells within the dosing interval at doses ≥ 300 mg in both monotherapy and combination therapy cohorts. Data are shown as mean ± SD.
[0250] Example 10: Soluble OX40 in BGB-A445 Monotherapy and Combination Therapy Across Doses
[0251] Soluble OX40 (sOX40) is shed from the surface of lymphocytes in response to T-cell activation and may indicate OX40 receptor engagement by OX40 agonist. sOX40 can be released from various tissues in addition to peripheral blood cells, and can serve as a systemic pharmacodynamic marker.
[0252] To measure sOX40 in patient serum, an assay was developed using the Meso Scale Discovery (MSD) platform. Briefly, a biotinylated capture antibody was captured to streptavidin on a plate surface. Detection antibodies were conjugated with electrochemiluminescence labels and bound to the analytes to complete the sandwich immunoassay. Once the immunoassay was complete, the plate was loaded into an MSD instrument, which measured the intensity of emitted light and provided a quantitative measure of each analyte in the sample.
[0253] As of a data update from 05 January 2024, sOX40 data were available for a total of 63 patients who were treated with BGB-A445 monotherapy (20 mg to 3600 mg every 3 weeks) in the dose-escalation and dose-expansion study portions and 48 patients on combination therapy (150 mg to 3600 mg every 3 weeks) with tislelizumab (200 mg) in the dose-escalation portion of the study. A stronger trend of sOX40 induction was found after long-term treatment at higher doses (≥ 1200 mg) in both monotherapy (Figure 11) and combination therapy (Figure 12) .
Claims
1.A method of treating cancer, the method comprising administering to a subject an effective dose of a non-competitive anti-OX40 antibody or antigen-binding fragment thereof in combination with an anti-PD1 antibody or antigen binding fragment thereof, whereinthe anti-OX40 antibody or antigen-binding fragment thereof specifically binds to human OX40 and comprises: a heavy chain variable region that comprises (a) a HCDR (Heavy Chain Complementarity Determining Region) 1 of SEQ ID NO: 12, (b) a HCDR2 of SEQ ID NO: 13, and (c) a HCDR3 of SEQ ID NO: 14; and a light chain variable region that comprises (d) a LCDR (Light Chain Complementarity Determining Region) 1 of SEQ ID NO: 15, (e) a LCDR2 of SEQ ID NO: 16, and (f) a LCDR3 of SEQ ID NO: 17; and the anti-PD1 antibody or antigen binding fragment thereof that comprises: a heavy chain variable region that comprises (a) a HCDR1 of SEQ ID NO: 1, (b) a HCDR2 of SEQ ID NO: 2, and (c) a HCDR3 of SEQ ID NO: 3; and a light chain variable region that comprises: (d) a LCDR1 of SEQ ID NO: 4, (e) a LCDR2 of SEQ ID NO: 5, and (f) a LCDR3 of SEQ ID NO: 6; andthe anti-OX40 antibody or antigen binding fragment thereof is administered at a dosage of from 20 mg –3600 mg.2.The method of claim 1, wherein the anti-OX40 antibody or antigen-binding fragment thereof comprises: a heavy chain variable region (VH) that comprises SEQ ID NO: 18, and a light chain variable region (VL) that comprises SEQ ID NO: 19; and the anti-PD1 antibody comprises a heavy chain variable region (VH) that comprises SEQ ID NO: 7, and a light chain variable region (VL) that comprises SEQ ID NO: 8.3.The method of claim 1 or claim 2, wherein the cancer is selected from the group consisting of breast cancer, colon cancer, anal cancer, peritoneal cancer, bladder cancer, pancreatic cancer, head and neck cancer, gastric cancer, gastroesophageal junction cancer, kidney cancer, liver cancer, small cell lung cancer, non-small cell lung cancer, ovarian cancer, cervical cancer, endometrial cancer, uterine cancer, skin cancer, mesothelioma, lymphoma, leukemia, myeloma, and sarcoma.4.The method of claim 3, wherein the cancer is a metastatic cancer.5.The method of any one of claims 1-4, wherein the treating results in a sustained anti-cancer response in the subject after cessation of the treatment.6.The method of any one of claims 1-5, wherein the anti-OX40 antibody or antigen binding fragment thereof is administered at a dosage of from 20 mg –2400 mg.7.The method of any one of claims 1-5, wherein the anti-OX40 antibody or antigen binding fragment thereof is administered at a dosage of 20 mg.8.The method of any one of claims 1-5, wherein the anti-OX40 antibody or antigen binding fragment thereof is administered at a dosage of 60 mg.9.The method of any one of claims 1-5, wherein the anti-OX40 antibody or antigen binding fragment thereof is administered at a dosage of 150 mg.10.The method of any one of claims 1-5, wherein the anti-OX40 antibody or antigen binding fragment thereof is administered at a dosage of 300 mg.11.The method of any one of claims 1-5, wherein the anti-OX40 antibody or antigen binding fragment thereof is administered at a dosage of 600 mg.12.The method of any one of claims 1-5, wherein the anti-OX40 antibody or antigen binding fragment thereof is administered at a dosage of 1200 mg.13.The method of any one of claims 1-5, wherein the anti-OX40 antibody or antigen binding fragment thereof is administered at a dosage of 2400 mg.14.The method of any one of claims 1-5, wherein the anti-OX40 antibody or antigen binding fragment thereof is administered at a dosage of 3600 mg.15.The method of any one of claims 1-14, wherein the anti-PD1 antibody or antigen binding fragment thereof is administered at a dosage of 200 mg.16.The method of any one of claims 1-15, wherein the anti-OX40 antibody or antigen binding fragment thereof is administered once a week.17.The method of any one of claims 1-15, wherein the anti-OX40 antibody or antigen binding fragment thereof is administered twice a week.18.The method of any one of claims 1-15, wherein the anti-OX40 antibody or antigen binding fragment thereof is administered three times a week.19.The method of any one of claims 1-15, wherein the anti-OX40 antibody or antigen binding fragment thereof is administered once every two weeks.20.The method of any one of claims 1-15, wherein the anti-OX40 antibody or antigen binding fragment thereof is administered once every three weeks.21.The method of any one of claims 1-15, wherein the anti-OX40 antibody or antigen binding fragment thereof is administered once a month.22.The method of any one of claims 1-21, wherein the anti-PD1 antibody or antigen binding fragment thereof is administered once every three weeks.
Citation Information
Patent Citations
Combination treatments and uses and methods thereof
CN108290947A
Anti-PD1 antibodies and application thereof serving as therapeutic agent and diagnostic agent
CN108715615A
Anti-ox40 antibodies and methods of use
CN112566935A
Methods of treating cancer using anti-OX40 antibodies in combination with anti-PD1 or anti-PDL1 antibodies
CN115151563A
Methods of treating cancer using Anti-ox40 antibodies and PD-1 axis binding antagonists
US20170000885A1
